Mental Health Services

Advanced Mental Health Services — TMS, qEEG & Ketamine

Advanced Mental Health Treatments

MedNova Partners connects patients and providers with cutting-edge mental health treatments — including TMS therapy, qEEG brain mapping, and ketamine treatment — for those who haven't found relief through traditional approaches.

01
FDA-Approved
TMS Treatment

Transcranial Magnetic Stimulation (TMS) is a non-invasive, FDA-approved therapy that uses magnetic pulses to stimulate specific regions of the brain linked to depression, OCD, anxiety, and other mental health conditions — with no surgery and no anesthesia required.

  • FDA-approved for depression, OCD & more
  • Non-invasive — no surgery, no anesthesia
  • Patients remain awake & alert throughout
  • Typical course: 5 days/week for 4–6 weeks
  • Sessions last 5–20 minutes each
  • Option for those who haven't responded to medication
  • Covered by most major insurance plans
02
Brain Mapping
qEEG Brain Scan

A qEEG (Quantitative Electroencephalography) is an advanced, non-invasive brain mapping scan that measures and analyzes electrical activity across different regions of the brain. It creates a detailed map of how your brain is functioning — identifying areas that are overactive or underactive — to guide more precise, personalized mental health treatment.

  • Painless, non-invasive brain activity scan
  • Electrodes placed on scalp — no radiation
  • Identifies brain patterns linked to mental health conditions
  • Helps diagnose depression, anxiety, ADHD, PTSD & more
  • Guides personalized TMS & treatment planning
  • Objective, data-driven approach to mental health care
  • Often used before or alongside TMS therapy
03
Treatment-Resistant
Ketamine & Spravato Treatment

We connect patients with two powerful ketamine-based treatments for treatment-resistant depression and PTSD — IV ketamine infusion therapy and Spravato® (esketamine) nasal spray by Johnson & Johnson, the first and only FDA-approved monotherapy for treatment-resistant depression. Both work by targeting the brain's glutamate system, offering rapid relief often within 24 hours for patients who haven't responded to traditional antidepressants.

  • Rapid relief — often within 24 hours
  • For treatment-resistant depression & PTSD
  • IV ketamine infusion — administered under medical supervision
  • Spravato® (esketamine) nasal spray — by Johnson & Johnson
  • FDA-approved monotherapy for treatment-resistant depression
  • Approved in 77 countries — administered to 140,000+ patients globally
  • Targets glutamate — a different mechanism than SSRIs
  • Clinical setting only — monitored throughout treatment
Featured Treatment
Spravato® (Esketamine)
By Johnson & Johnson · FDA-Approved Nasal Spray

Spravato® is the first and only FDA-approved monotherapy for treatment-resistant depression — a prescription esketamine nasal spray by Johnson & Johnson that delivers rapid symptom improvement as early as 24 hours, without requiring a daily oral antidepressant.

Approved following FDA Priority Review in January 2025, Spravato® has now been administered to over 140,000 patients across 77 countries — with a well-established clinical safety profile built on more than a decade of research and 31 clinical trials.

FDA Status
First & only FDA-approved monotherapy for treatment-resistant depression (Jan 2025)
How It Works
Esketamine nasal spray — targets glutamate, the brain's most abundant excitatory neurotransmitter
Speed of Relief
Rapid improvement in depressive symptoms as early as 24 hours — sustained through 28 days
Global Reach
Approved in 77 countries, administered to 140,000+ patients worldwide over 6+ years
Available Through MedNova Partners
MedNova Partners connects patients and providers with Spravato® treatment. Contact us to learn how to access this breakthrough therapy for your patients or for yourself.

Why MedNova for Mental Health

State-of-the-Art Care for the Mind

At MedNova Partners, we are always working to bring state-of-the-art new technology and treatments to home health agencies and patients. Mental health is no exception. We connect patients and providers with the most advanced, evidence-backed mental health services available today.

Whether you are a home health agency looking to add mental health services for your patients, or a patient seeking a new path forward after other treatments haven't worked — MedNova Partners can connect you with the right providers and treatments.

Connect With Us About Mental Health Services
Conditions We Help Connect Treatment For
  • Major Depressive Disorder (MDD)
  • Treatment-Resistant Depression
  • Obsessive-Compulsive Disorder (OCD)
  • Post-Traumatic Stress Disorder (PTSD)
  • Anxiety disorders
  • ADHD & attention difficulties
  • Chronic pain linked to mental health
  • Suicidal ideation (under medical supervision)
Important Note:

MedNova Partners connects patients and providers with mental health treatment services. TMS is FDA-approved for depression, OCD, and certain other conditions. Spravato® (esketamine) is FDA-approved as a monotherapy for treatment-resistant depression and is available only through the Spravato® REMS program under medical supervision. IV ketamine infusion therapy is not currently FDA-approved for depression but may be prescribed off-label by qualified physicians. qEEG brain mapping is a diagnostic tool used to guide personalized treatment planning. All treatments should be discussed with a qualified healthcare provider. Please consult your physician before beginning any new treatment.